Jazz Pharmaceuticals plc

NasdaqGS:JAZZ Stock Report

Market Cap: US$7.1b

Jazz Pharmaceuticals Valuation

Is JAZZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of JAZZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: JAZZ ($119.24) is trading below our estimate of fair value ($684.78)

Significantly Below Fair Value: JAZZ is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for JAZZ?

Key metric: As JAZZ is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for JAZZ. This is calculated by dividing JAZZ's market cap by their current earnings.
What is JAZZ's PE Ratio?
PE Ratio15.6x
EarningsUS$463.16m
Market CapUS$7.06b

Price to Earnings Ratio vs Peers

How does JAZZ's PE Ratio compare to its peers?

The above table shows the PE ratio for JAZZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average24.2x
ELAN Elanco Animal Health
32.4x2.7%US$6.6b
CORT Corcept Therapeutics
41.8x41.0%US$5.7b
PBH Prestige Consumer Healthcare
19.8x5.3%US$4.1b
OGN Organon
2.9x-7.1%US$3.8b
JAZZ Jazz Pharmaceuticals
15.6x16.7%US$7.1b

Price-To-Earnings vs Peers: JAZZ is good value based on its Price-To-Earnings Ratio (15.6x) compared to the peer average (24.2x).

Price to Earnings Ratio vs Industry

How does JAZZ's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

12 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
2.9x-7.1%US$3.76b
NDOI Endo
0.6xn/aUS$1.91b
PROC Procaps Group
1.2xn/aUS$59.68m
KPRX Kiora Pharmaceuticals
1.8x-40.4%US$9.59m
JAZZ 15.6xIndustry Avg. 20.1xNo. of Companies12PE01224364860+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: JAZZ is good value based on its Price-To-Earnings Ratio (15.6x) compared to the US Pharmaceuticals industry average (20.1x).

Price to Earnings Ratio vs Fair Ratio

What is JAZZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

JAZZ PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.6x
Fair PE Ratio26x

Price-To-Earnings vs Fair Ratio: JAZZ is good value based on its Price-To-Earnings Ratio (15.6x) compared to the estimated Fair Price-To-Earnings Ratio (26x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst JAZZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$119.24
US$177.53
+48.9%
16.4%US$230.00US$128.00n/a19
Nov ’25US$110.45
US$179.39
+62.4%
16.5%US$230.00US$120.00n/a18
Oct ’25US$109.04
US$178.78
+64.0%
16.8%US$230.00US$120.00n/a18
Sep ’25US$115.98
US$175.63
+51.4%
18.1%US$230.00US$120.00n/a19
Aug ’25US$114.38
US$175.00
+53.0%
18.2%US$230.00US$113.00n/a19
Jul ’25US$106.47
US$179.16
+68.3%
16.2%US$230.00US$117.00n/a19
Jun ’25US$105.25
US$180.89
+71.9%
16.7%US$230.00US$117.00n/a18
May ’25US$110.31
US$188.21
+70.6%
15.6%US$230.00US$121.00n/a20
Apr ’25US$118.98
US$188.76
+58.6%
14.9%US$230.00US$131.00n/a20
Mar ’25US$118.85
US$186.89
+57.3%
15.6%US$230.00US$131.00n/a19
Feb ’25US$123.68
US$188.05
+52.0%
16.0%US$235.00US$135.00n/a19
Jan ’25US$123.00
US$190.94
+55.2%
15.8%US$240.00US$135.00n/a18
Dec ’24US$119.11
US$193.00
+62.0%
14.6%US$240.00US$135.00n/a18
Nov ’24US$127.34
US$199.00
+56.3%
11.9%US$240.00US$140.00US$110.4518
Oct ’24US$129.44
US$200.24
+54.7%
12.0%US$240.00US$140.00US$109.0417
Sep ’24US$143.76
US$200.24
+39.3%
12.0%US$240.00US$140.00US$115.9817
Aug ’24US$129.54
US$200.53
+54.8%
11.6%US$240.00US$140.00US$114.3817
Jul ’24US$123.97
US$199.75
+61.1%
12.0%US$240.00US$140.00US$106.4716
Jun ’24US$129.12
US$200.67
+55.4%
9.3%US$240.00US$165.00US$105.2518
May ’24US$141.37
US$201.72
+42.7%
8.0%US$240.00US$180.00US$110.3118
Apr ’24US$146.33
US$202.28
+38.2%
7.6%US$240.00US$180.00US$118.9818
Mar ’24US$140.51
US$200.63
+42.8%
7.9%US$240.00US$180.00US$118.8519
Feb ’24US$157.77
US$200.63
+27.2%
7.9%US$240.00US$180.00US$123.6819
Jan ’24US$159.31
US$200.00
+25.5%
7.4%US$240.00US$180.00US$123.0019
Dec ’23US$156.54
US$200.11
+27.8%
7.4%US$240.00US$180.00US$119.1119
Nov ’23US$145.61
US$198.37
+36.2%
8.3%US$240.00US$170.00US$127.3419

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%